Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and Pralatrexate
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Decitabine (Primary) ; Pembrolizumab (Primary) ; Pralatrexate (Primary)
- Indications Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- 20 Nov 2017 Planned initiation date changed from 1 Oct 2017 to 1 Jan 2018.
- 25 Aug 2017 Planned initiation date changed from 10 Sep 2017 to 1 Oct 2017.
- 09 Aug 2017 New trial record